The objectives of this work were to: (1) Determine if prostate and penile tissue levels of endothelin-1 (ET-1) are increased in a rat following pelvic irradiation. (2) Determine if an ETa receptor antagonist (BQ-123) potentiates erectile function in these irradiated animals. Rats were divided into three study groups: control, 1000 cGy and 2000 cGy. The experimental groups received a single dose of radiation to the pelvic region. A time course was established to measure the effects of irradiation on prostate and penile tissue levels of endothelin-1 (ET-1)-like immunoreactivity. The effect of intracavernous injection of BQ-123 (25 m mga30 m ml) was evaluated by measuring intracavernous pressure (ICP) following cavernous nerve electrical ®eld stimulation. In the 2000 cGy group, a signi®cant rise in ET-1-like immunoreactivity tissue levels was observed at 20 days. A signi®cant decrease in ICP was recorded in the 1000 and 2000 cGy irradiated rats compared to the control group. Only the 2000 cGy group had a signi®cant improvement in erectile function following BQ-123 administration. A signi®cant improvement was observed 20 min postadministration, lasted 90 min, and was back to pre-administered levels at 120 min. The conclusion made was that radiation-induced impotence in irradiated rats is associated with an increased production of ET-1. Preliminary results are suggestive that ETa receptor antagonist may be of use to reverse such radiation-induced impotence in these irradiated animals.
Introduction
Radiation therapy to the pelvis and prostatic fossa is a current mainstay of therapy for men with localized prostate cancer. Erectile dysfunction is a known side effect following irradiation. 1, 2 The literature is replete with studies demonstrating the association between radiotherapy and impotence, however little insight into the true pathogenesis is known. The pathophysiology of this complication has been linked mainly to blood vessel injury and to damage of the nerves that innervate the corporal smooth muscle. 3 ± 5 Loss of sexual function in men undergoing radical pelvic irradiation is common, and should be a major discussion point between the patient and his physician. The association between erectile dysfunction and radiotherapy has been reported in a number of studies. 3, 6, 7 Radiationassociated impotence (RAI) varies from 22% to 84%. Two characteristics of RAI are variable onset and irreversibility. Radiation-associated impotence occurs anytime after radiation therapy, and has been reported many years following treatment. Importantly, once it manifests, it is usually progressive and irreversible.
Radiotherapy can cause damage to the blood vessel wall contractile elements and its lining, the endothelial cells. Ionizing radiation 8, 9 causes damage to both of these functional compartments of the blood vessel. This could result in pathological conditions, such as the one observed in RAI. In vitro data from Shenouda et al 10 demonstrated an increased production of vasoactive compounds such as ET-1 by human endothelial cells upon exposure to ionizing radiation. If altered, this increased ET-1 production would upset the delicate equilibrium and thus lead to abnormal vascular tone. ET-1 is an important vasoconstrictor with mitogenic activity that is localized within prostatic and penile tissues. Furthermore, there is experimental evidence that ET-1 mediated contractile effects can be involved in erectile dysfunction. 11 The current study is intended to show that upon radiation exposure to the pelvic region of a rat, there is an increased ET-1 like immunoreactivity content in prostatic and penile tissues. Furthermore, the effects of a locally administered ETa receptor antagonist on the intracavernosal pressure was determined in vivo.
Materials and methods
Ninety Sprague ± Dawley rats received irradiation to the pelvic region. For the radioimmunoassays three groups were studied: control (no irradiation) (n 20), 1000 cGy (n 20), and 2000 cGy (n 20) and evaluated at the following time points: 1 day, 10 days, 20 days, and 1 month. Rats evaluated for intracorporal pressure rise with electrical ®eld stimulation of the cavernous nerve study were divided into two study groups: control (n 10) and 2000 cGy (n 20) and evaluated at 1 month.
Animals were anaesthetized using pentobarbital (45 mgakg i.p.). Each rat was immobilized in the radiation ®eld. Radiation was delivered to the prostatic region by a 4.564.5 cm ®eld in a single fraction. Special attention was given to shield both testes by using a lead shield. Radiation given to the rats was supervised by one of us (GS). Radiation was delivered by a beam 250-kVp at a dose rate of 424 cGyamin.
Histological analysis was performed to con®rm radiation-induced damage to the prostate. Rat prostatic tissue was ®xed in 10% buffered formaldehyde. Tissues were step-sectioned at 3 mm intervalsaparaf®n-embedded in toto, and stained with hematoxylin ± eosin.
ET-1 tissue content was evaluated following an extraction procedure by boiling the tissue in an extraction buffer for 10 minutes. The extraction buffer was composed of: 2 M acetic acid, 11.4 mM HCl, 1 mM disodium ethylenediamine tetraacetate (EDTA), and 1 mM dithiothreitol, and several protease inhibitors: 1 mM 4-(2-aminoethyl)-benzesulfonyl¯uoride-HCl (AEBSF) (Boehringer), 2 mgaml aprotinin (Calbiochem), 100 mM leupeptin (Calbiochem), 1 mgaml cystatin (Calbiochem), and 1 mM benzamidine (Sigma). After boiling, all samples were cooled on ice before homogenization for 2 minutes using a polytron (Brinkman). Subsequently, the samples were centrifuged at 3835 g at 4 C for 15 min. The supernatant was then subjected to lyophylization. The lyophylized powder was then transferred to a fresh tube and this was stored at 780 C until analysis of ET-1 content. Endothelin concentrations were measured by radioimmunoassay. A commercially available ET-1 kit (Phoenix, CA) was used for the RIA, with an antibody which recognizes ET-1 at 100%, ET-2 and ET-3 at 7%, and human Big-ET-1 at 17%.
The samples were reconstituted in the supplied RIA buffer before the rabbit anti-ET-1 sera addition followed by an overnight incubation at 4 C. The following day, 125 I-ET-1 was added; the samples were vortexed and incubated at 4 C overnight. On day 3, goat anti-rabbit IgG serum and normal rabbit serum were added and the mixture was incubated at room temperature for 120 min. Additional RIA buffer was added, and tubes were centrifuged at 3000 rpm for 20 min. The supernatant was carefully aspirated off avoiding dislodging the pellet, which was then subjected to quanti®cation in a gcounter. ET-1 protein levels were then determined by plotting the value of the unknowns on the standard curve.
Rats were anaesthetized using sodium pentobarbital (45 mgakg i.p.). The right carotid artery was catheterized with PE-50 tubing for monitoring the systemic blood pressure. Through a lower mid-line abdominal incision, the lateral prostate space was dissected and the major pelvic ganglia (MPG) identi®ed, under 610 magni®cation. Through a perineal ± scrotal incision, the right penile crus was exposed by spreading the overlying ischiocavernous muscle. A 23G needle ®lled with a dilute heparin solution (50 Uaml) and connected to PE-50 tubing was inserted into the penile crus. Systemic pressure and maximum intracavernous pressure (ICP) were measured (in cm H 2 0) and recorded using Labview 2 program software (National Instruments, TX). The cavernous nerve was freed from its fascial attachments and hooked using a bipolar steel electrode 3 ± 4 mm distal to the MPG. Electrostimulation was carried out with a delicate stainless steel bipolar hook electrode. The two poles of the electrode were separated by 2 mm with each pole 0.2 mm in diameter. Monophasic rectangular pulses were delivered from the module at a pulse width of 0.2 ms, frequency of 20 pulsesas, and current of 2 mA. The duration of stimulation was 40 s. Each animal was stimulated twice before and after injection of the ETa receptor antagonist BQ-123 (American Peptide, CA). The resting period between stimulations was 10 min. We have shown previously that 10 min rest provides reproducible results (unpublished results). The left penile crus was exposed by spreading the overlying ischiocavernous muscle. BQ-123 (25 mga30 ml; 17% DMSO; intracavernous) was administered via a PE-20 line to the left crus. Sham-irradiated rats underwent the sameprocedurewithvehicleratherthantheantagonist.
The results are expressed as means and standard error of the mean. Differences between groups were compared using a one-way analysis of variance (ANOVA), and P values`0.05 were considered to be statistically signi®cant.
Results
A rat prostate sample was observed histologically, two months following radiation, to con®rm radiation-associated damage. Approximately 65 ± 70% of New New insights into the role of endothelin-1 SL Merlin et al the prostatic glands were atrophied, being characterized by a loss of intraglandular infolding, a low globular basophilic material or debris of undetermined nature. The non-atrophic glands appear with a somewhat regional pattern of distribution, including the most peripheral aspect of the prostate. The lining epithelium of latter glands shows a signi®cant degree of radiation-related atypia, including: abnormal cell polarity, strati®ca-tion, nucleomegaly with hyperchromasia and distinctive nucleoli, binucleation, increased volume of cytoplasm, and occasional cells with cytoplasmic andaor nuclear vacuolar changes. Thus, the rat prostate was consistent with radiation-induced glandular damage, including focal near-end stage glandular atrophy. Histological examinations were performed to assess the effectiveness of the shielding of the testes. Our results show that the shielding of the testes was effective. Histological analysis revealed well preserved tissue with no speci®c pathological alteration. Measurement of serum testosterone levels showed that they were not signi®cantly affected by irradiation. Tissue levels of ET-1 were assessed in prostate and penile tissues. A time course of ET-1 in penile tissue showed no signi®cant level of ET-1 (1.2 pgag tissue AE 0.9) in the 1000 cGy group compared to the control (Figure 1a) . However, in the 2000 cGy group, there was a signi®cant increased in ET-1 at 20 days (4.8 pgag tissue AE 1.8) and 30 days (10 pgag tissue AE 4.3). A time course of ET-1 in prostate tissue showed a similar pattern (Figure 1b) . There was no signi®cant difference in the ET-1 levels in the 1000 cGy group compared to the control group. However, there was a signi®cant increase in the 2000 cGy group at 20 days (8 pgag tissue AE 2.1) and 30 days (15 pgag tissue AE 3.1).
Electrostimulation of the cavernous nerve revealed signi®cant differences in the mean maximal intracavernous pressures among groups. Before injection of the BQ-123, the control group had a signi®cantly higher mean maximal intracavernous pressure compared to the two irradiated groups New insights into the role of endothelin-1 SL Merlin et al 2b) until it reached a maximum at 1 h (Figure 2c) . After 2 h, the mean maximal intracavernosal pressure of the 2000 cGy group was no longer signi®cantly affected (Figure 2d ). During this time, a qualitative assessment was done to observe the rigidity of the rat penis. As intracavernosal pressures rose, the rat penis was observed to increase in rigidity. Subsequently, when pressures fell after 1 h, the rigidness of the rat penis was no longer apparent.
Discussion
Advances have been achieved over the past decade in elucidating many important mechanisms in erection physiology. Normal erectile function is characterized by a delicate balance of vasoconstricting and vasorelaxing effects. The endothelial cell has a unique intrinsic feature; it produces ET-1, the most potent vasoconstrictor peptide, and yet it also releases an equally potent vasodilator substance, nitric oxide (NO). ET is known to cause an initial and transient vasodilation followed by a sustained vasoconstriction. The vasodilation is thought to be via the activation of ETb receptor which causes the release of vasodilators, one of which is NO.
Our objective in this pilot study was to determine whether a rat animal model of erection, exposed to pelvic irradiation comparable to what is commonly used in prostate cancer would: (1) alter tissue levels of ET-1; (2) reduce cavernous nerve electric ®eld stimulation-induced erection in vivo; and (3) if speci®c ETa receptor antagonist could reverse this effect.
Single doses of irradiation were used in these experiments in order to ®nd a practical and reasonable range of doses in this animal model. It is clear that the use of single doses of radiation does not necessarily re¯ect the clinical fractionation used in modern radiotherapy schedules, however the use of single doses may be the initial step in order to investigate whether or not radiotherapy to the prostate leads to increase in ET-1 production, taking into consideration the limitations encountered in animal laboratory studies.
Based on the facts that the majority of the ET-1 is found in tissues, tissue levels of ET-1 was assessed. Our results shows signi®cant increase in tissue levels of ET-1 in the 2000 cGy group at 1 month. This increase in ET-1 could have a deleterious effect on the penile vasculature. This post-irradiation increased level suggest a possible role in RAI in which increased corporal smooth muscle contractility or an impaired corporal smooth muscle relaxation is present. Because it was shown in a previous study that radiation exposure decreases the level of NOS in the nerves that innervate the penis, 6 and because NO regulates the expression of ET-1, perhaps RAI might involve a loss of negative feedback. Furthermore, this increased ET-1 level could, in part, be responsible for the accelerated atherosclerosis seen in the pelvic vasculature of RAI patients. 3 These ®ndings are consistent with ®nd-ings obtained in patients evaluated by angiogram. This increased ET-1 level could be involved in the atherosclerotic lesion development by acting as an autocrine growth factor for smooth muscle cells in the corpus cavernosum and pelvic vasculature.
An in vivo study was carried out to validate our hypothesis that radiation alters erectile function. An ETa receptor antagonist was administered directly to the penile circulation to determine if we could potentiate the erection observed in a rat animal model exposed to radiation. One could determine that upon radiation exposure, there is an increased release of ET-1, which compromises the blood supply to the penis. Increased amounts of ET-1 could be responsible for the erectile dysfunction by either altering the capacity of the smooth muscle to relax or by inducing pathological changes in the pelvic vasculature. 13, 14 It is also known that other vascular risk factors such as cigarette smoking, hypertension, atherosclerotic diet, diabetes, and family history are important factors that could increase the incidence of post-radiation impotence. 3 Our in vivo model shows an improvement of erection following injection of the ETa receptor antagonist.
The literature is replete with studies implicating altered levels of nitric oxide (NO) as a possible cause of erectile dysfunction. In this study, we address another possible mediator of erectile dysfunction, ET-1, and its possible role in erectile dysfunction in radiation-associated impotence. The potentiation of erectile function on this rat animal model by an ET-1 antagonist offers some insight into the pathophysiology of RAI. Whether this increase in function acts also through an altered ET-1 receptor expression has yet to be determined. It is possible that ET-1 is not acting alone. Other mediators, such as angiotensin-II (AT-II) may play a role in RAI. In many systems, there is an inter-relationship between ET-1 and AT-II. AT-II stimulates ET gene expression in endothelial cells, 15 vascular smooth muscle cells, 16 and endothelial cells. 17 It would be interesting to show whether co-administration of an ETa receptor antagonist and an AT-II receptor antagonist would have synergistic effects in RAI. Previous studies have shown this effect in various tissues such as in the heart and blood vessels. 18, 19 This preliminary study describes a possible role for ET-1 in RAI. However, future studies should be carried out to describe in a more accurate manner the role of ET-1. Such studies could utilize more optimal radiation doses, longer time intervals could be assessed. Further experimentation is needed in order to determine the relevance of the ®ndings of the current study to the real clinical setting in patients with prostate cancer.
To achieve an erection adequate for sexual intercourse, an intact neurovascular mechanism New insights into the role of endothelin-1 SL Merlin et al must be present. Pelvic radiotherapy is thought to damage both vascular and neural components within the penis. The current literature supports the concept of radiotherapy producing a primary effect on the vasculature which is progressive over the course of months to years in man. The future holds promise of new antagonists, able to modify the vasoconstricting actions of circulating agents, coupled with an improved understanding of the anatomy and physiology of erection.
